CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 168 enrolled
Drug / intervention
Staccato Loxapine +1 moredrug
Likely dose
Staccato Placebo 0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00489476
NCT00489476Phase 2Completed

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Migraine Headache

Alexza Pharmaceuticals, Inc.·interventional·Posted Jun 21, 2007·Updated Jul 6, 2017

In Brief

A Phase 2 clinical trial evaluating Staccato Loxapine and Staccato Placebo for Migraine. Completed, enrolled 168 participants across 1 site.

Detailed Summary

The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 21, 2007
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.0 years ago

Interventions

Staccato Loxapinedrug

Staccato Placebodrug

Placebo aerosol inhalation (0mg)